Taysha Gene Therapies to Release Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 11
Taysha Gene Therapies (Nasdaq: TSHA) will report its financial results for Q2 2022 on August 11, 2022, at 8:00 AM ET. This pivotal-stage company focuses on developing AAV-based gene therapies for central nervous system diseases. The conference call will provide insights into the company's financial performance and updates on its gene therapy pipeline. Taysha's mission is to eradicate monogenic CNS diseases through rapid translation of treatments from research to clinical applications, leveraging a fully integrated platform to improve patients' lives.
- None.
- None.
DALLAS, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced that it will report its financial results for the second quarter ended June 30, 2022, and host a corporate update conference call and webcast on Thursday, August 11, 2022, at 8:00 AM Eastern Time.
| Conference Call Details | |
| Thursday, August 11, at 8:00 AM Eastern Time / 7:00 AM Central Time | |
| Toll Free: | 877-407-0792 |
| International: | 201-689-8263 |
| Conference ID: | 13730848 |
| Webcast: | https://ir.tayshagtx.com/news-events/events-presentations |
About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives. More information is available at www.tayshagtx.com.
Company Contact:
Kimberly Lee, D.O.
Chief Corporate Affairs Officer
Taysha Gene Therapies
klee@tayshagtx.com
Media Contact:
Carolyn Hawley
Evoke Canale
carolyn.hawley@evokegroup.com
FAQ
What are the financial results for Taysha Gene Therapies for Q2 2022?
When is Taysha Gene Therapies' next conference call?
What is the focus of Taysha Gene Therapies?
What time is the Taysha Gene Therapies conference call in Central Time?
